GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aleafia Health Inc (HAM:ARAH) » Definitions » Debt-to-EBITDA

Aleafia Health (HAM:ARAH) Debt-to-EBITDA : -1.31 (As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Aleafia Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aleafia Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €8.97 Mil. Aleafia Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €22.66 Mil. Aleafia Health's annualized EBITDA for the quarter that ended in Mar. 2023 was €-24.16 Mil. Aleafia Health's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was -1.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aleafia Health's Debt-to-EBITDA or its related term are showing as below:

HAM:ARAH's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.81
* Ranked among companies with meaningful Debt-to-EBITDA only.

Aleafia Health Debt-to-EBITDA Historical Data

The historical data trend for Aleafia Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aleafia Health Debt-to-EBITDA Chart

Aleafia Health Annual Data
Trend Jan12 Jan13 Jan14 Jan15 Jan16 Oct17 Dec18 Dec19 Dec20 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -2.89 -0.25 -2.48

Aleafia Health Quarterly Data
Oct17 Jan18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Jun22 Sep22 Dec22 Mar23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 28.62 1.04 -0.49 -1.31

Competitive Comparison of Aleafia Health's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Aleafia Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aleafia Health's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aleafia Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aleafia Health's Debt-to-EBITDA falls into.



Aleafia Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aleafia Health's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.971 + 22.66) / -12.754
=-2.48

Aleafia Health's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.971 + 22.66) / -24.156
=-1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2023) EBITDA data.


Aleafia Health  (HAM:ARAH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Aleafia Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aleafia Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aleafia Health Business Description

Traded in Other Exchanges
N/A
Address
85 Basaltic Road, Concord, ON, CAN, L4K 1G4
Aleafia Health Inc is a vertically integrated cannabis health and wellness company which owns three cannabis product and cultivation facilities where it produces a diverse portfolio of commercially high-margin derivative products including oils, capsules and sprays. The company operates national network of medical cannabis clinics and has seen over 60,000 patients to date.

Aleafia Health Headlines

No Headlines